Condition
Autoimmune Disorders
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Recruiting4
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT02972801Not ApplicableRecruiting
Testicular Tissue Cryopreservation for Fertility Preservation
NCT06434363Phase 1RecruitingPrimary
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
NCT07103746Phase 2RecruitingPrimary
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
NCT05671757Phase 1RecruitingPrimary
Daratumumab in Primary Antiphospholipid Syndrome
NCT01489956Early Phase 1TerminatedPrimary
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
Showing all 5 trials